Search Results - "BARTELINK, H"

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade by Milberg, Oleg, Gong, Chang, Jafarnejad, Mohammad, Bartelink, Imke H., Wang, Bing, Vicini, Paolo, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S.

“…Over the past decade, several immunotherapies have been approved for the treatment of melanoma. The most prominent of these are the immune checkpoint…”
Get full text

SP-0192: Biomarkers and the prediction of outcome in breast conserving therapy by Bartelink, H

Get full text

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer by Jafarnejad, Mohammad, Gong, Chang, Gabrielson, Edward, Bartelink, Imke H., Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S.

“…Immunotherapy and immune checkpoint blocking antibodies such as anti-PD-1 are approved and significantly improve the survival of advanced non-small cell lung…”
Get full text

SP-0137 AGAINST THE MOTION by Bartelink, H

Get full text

Modelling mixed forest growth: a review of models for forest management by Porté, A., Bartelink, H.H.

“…Most forests today are multi-specific and heterogeneous forests (‘mixed forests’). However, forest modelling has been focusing on mono-specific stands for a…”
Get full text

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis by Pignon, Jean-Pierre, Le, Quynh Thu, Grau, Cai, Hackshaw, Allan, Ghi, Maria Grazia, Sanguineti, Giuseppe, O'Sullivan, Brian, Vokes, Everett E, Cruz Hernandez, Juan J, Budach, Volker, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Simes, John, Zhong, Lai-Ping, Bourhis, Jean, Aupérin, Anne, Agarwal, J., Argiris, A., Aupérin, A., Bacigalupo, A., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Brizel, D., Budach, V., Burtness, B., Campbell, B., Chabaud, S., Chamorey, E., Chaukar, D., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Driessen, C.M.L., Fortpied, C., Garaud, P., Garden, A.S., Ghadjar, P., Ghosh Laskar, S., Grau, C., Gregoire, V., Hackshaw, A., Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Johansen, J., Julieron, M., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Licitra, L., Lee, P., Li, Y., Lotayef, M., Maciejewski, B., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Nilsson, P., Orecchia, R., Parmar, M.K.B., Pointreau, Y., Poulsen, M.G., Quon, H., Rosenthal, D.I., Sanguineti, G., Simes, J., Simon, C., Sire, C., Staar, S., Strojan, P., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Torri, V., Tripcony, L., Tseroni, V., van Tinteren, H., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Wolf, G.T., Wong, S.J., Wu, J.S., Zaktonik, B., Zackrisson, B.

“…Randomised, controlled trials and meta-analyses have shown the survival benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the…”
Get full text

Battling the obesity epidemic with a school-based intervention: Long-term effects of a quasi-experimental study by Willeboordse, M, Bartelink, N. H. M, van Assema, P, Kremers, S. P. J, Savelberg, H. H. C. M, Hahnraths, M. T. H, Vonk, L, Oosterhoff, M, van Schayck, C. P, Winkens, B, Jansen, M. W. J

“…Background School-based health-promoting interventions are increasingly seen as an effective population strategy to improve health and prevent obesity…”
Get full text

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis by Bartelink, Imke H, PhD, Lalmohamed, Arief, PharmD, van Reij, Elisabeth M L, PharmD, Dvorak, Christopher C, MD, Savic, Rada M, PhD, Zwaveling, Juliette, PharmD, Bredius, Robbert G M, MD, Egberts, Antoine C G, Prof, Bierings, Marc, MD, Kletzel, Morris, MD, Shaw, Peter J, MD, Nath, Christa E, PhD, Hempel, George, MD, Ansari, Marc, MD, Krajinovic, Maja, Prof, Théorêt, Yves, PhD, Duval, Michel, Prof, Keizer, Ron J, PharmD, Bittencourt, Henrique, MD, Hassan, Moustapha, MD, Güngör, Tayfun, MD, Wynn, Robert F, MD, Veys, Paul, MD, Cuvelier, Geoff D E, MD, Marktel, Sarah, MD, Chiesa, Robert, MD, Cowan, Morton J, MD, Slatter, Mary A, MD, Stricherz, Melisa K, PharmD, Jennissen, Cathryn, PharmD, Long-Boyle, Janel R, PharmD, Boelens, Jaap Jan, Dr

“…Summary Background Intravenous busulfan combined with therapeutic drug monitoring to guide dosing improves outcomes after allogeneic haemopoietic cell…”
Get full text

Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen by Bognàr, T. (Tim), Kingma, J. S. (Jurjen), Smeijsters, E. H. (Erin), van der Elst, K. C. M. (Kim), de Kanter, C. T. M. (Klaartje), Lindemans, C. A. (Caroline), Egberts, A. C. G. (Toine), Bartelink, I. H. (Imke), Lalmohamed, A. (Arief)

“…Busulfan exposure has previously been linked to clinical outcomes, hence the need for therapeutic drug monitoring (TDM). Study objective was to evaluate the…”
Get full text

Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing by Admiraal, Rick, van Kesteren, Charlotte, Jol-van der Zijde, Cornelia M., van Tol, Maarten J. D., Bartelink, Imke H., Bredius, Robbert G. M., Boelens, Jaap Jan, Knibbe, Catherijne A. J.

“…Background and Objectives To prevent graft-versus-host disease and rejection in hematopoietic cell transplantation (HCT), children receive Thymoglobulin ® , a…”
Get full text

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial by Atmowihardjo, Leila N, Schippers, Job R, Duijvelaar, Erik, Bartelink, Imke H, Bet, Pierre M, Swart, Noortje E L, van Rein, Nienke, Purdy, Keith, Cavalla, David, McElroy, Andrew, Fritchley, Sarah, Vonk Noordegraaf, Anton, Endeman, Henrik, van Velzen, Patricia, Koopmans, Matty, Bogaard, Harm Jan, Heunks, Leo, Juffermans, Nicole, Schultz, Marcus J, Tuinman, Pieter R, Bos, Lieuwe D J, Aman, Jurjan

“…A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic respiratory failure due to pulmonary vascular hyperpermeability. The tyrosine kinase…”
Get full text

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients by BARTELINK, Imke H, WOLFS, Tom, JONKER, Martine, DE WAAL, Marjolein, EGBERTS, Toine C. G, VERVERS, Tessa T, BOELENS, Jaap J, BIERINGS, Marc

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial by Dickhoff, Chris, Senan, Suresh, Schneiders, Famke L, Veltman, Joris, Hashemi, Sayed, Daniels, Johannes M A, Fransen, Marieke, Heineman, David J, Radonic, Teodora, van de Ven, Peter M, Bartelink, Imke H, Meijboom, Lilian J, Garcia-Vallejo, Juan J, Oprea-Lager, Daniela E, de Gruijl, Tanja D, Bahce, Idris

“…The likelihood of a tumor recurrence in patients with T3-4N0-1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due…”
Get full text

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model by Wang, Hanwen, Milberg, Oleg, Bartelink, Imke H, Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Santa-Maria, Cesar A, Popel, Aleksander S

“…The low response rate of immune checkpoint blockade in breast cancer has highlighted the need for predictive biomarkers to identify responders. While a number…”
Get full text

Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer by Hooning, Maartje J., Botma, Akke, Aleman, Berthe M. P., Baaijens, Margreet H. A., Bartelink, Harry, Klijn, Jan G. M., Taylor, Carolyn W., van Leeuwen, Flora E.

“…Background Radiotherapy for breast cancer as delivered in the 1970s has been associated with increased risk of cardiovascular disease, but recent studies of…”
Get full text

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period by Bosma, S. C. J., van der Leij, F., van Werkhoven, E., Bartelink, H., Wesseling, J., Linn, S., Rutgers, E. J., van de Vijver, M. J., Elkhuizen, P. H. M.

“…The purpose of this study was to study the impact of changes in clinical practice on outcome in patients treated with breast-conserving therapy (BCT) over a…”
Get full text

SP-0060: Image and biological guided adaptive radiotherapy; results from the ARTFORCE project by Bartelink, H, ARTFORCE, X

Get full text

Process evaluation of the healthy primary School of the Future: the key learning points by Bartelink, N H M, van Assema, P, Jansen, M W J, Savelberg, H H C M, Moore, G F, Hawkins, J, Kremers, S P J

“…While schools have potential to contribute to children's health and healthy behaviour, embedding health promotion within complex school systems is challenging…”
Get full text

Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients by Huntjens, Daan W, Dijkstra, Jacob A, Verwiel, Lisanne N, Slijkhuis, Mirjam, Elbers, Paul, Welkers, Matthijs R A, Veldkamp, Agnes I, Kuijvenhoven, Marianne A, de Leeuw, David C, Abdullah-Koolmees, Heshu, Kuipers, Maria T, Bartelink, Imke H

“…Herpes simplex virus (HSV) and cytomegalovirus (CMV) are DNA viruses that are common among humans. Severely immunocompromised patients are at increased risk of…”
Get full text

Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors by Gong, Chang, Anders, Robert A, Zhu, Qingfeng, Taube, Janis M, Green, Benjamin, Cheng, Wenting, Bartelink, Imke H, Vicini, Paolo, Wang, Bing, Popel, Aleksander S

“…Quantitative characterization of the tumor microenvironment, including its immuno-architecture, is important for developing quantitative diagnostic and…”
Get full text